Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 4Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Sarcoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinoma 1Subcutaneous panniculitis-like T-cell lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Breast Cancer Organoids 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Temozolomide 23Surgical Procedures, Operative 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × pirarubicin × Clear all
NCT03342300 2020-05-19

PDVPSTS

Peking University People's Hospital

Phase 2/3 Withdrawn
Sarcoma

Sarcoma

NCT04126811 2019-10-15

Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
120 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡